New Key Statistics Module, Z-Score and F-Score
OTCPK:ARTH Key Ratios
| Market Cap $ M | 0.91 |
| Enterprise Value $ M | 10.25 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | 0.03 |
| Price/Book | -- |
| Price/Sales | 6.26 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | -- |
| EPS (TTM) $ | -2.86 |
| Beneish M-Score | -29.46 |
| 10-y EBITDA Growth Rate % | 18.20 |
| 5-y EBITDA Growth Rate % | 29.20 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -1.18 |
| EV-to-EBITDA | -1.18 |
| PEG | -- |
| Shares Outstanding M | 4.44 |
| Net Margin (%) | -8,230.20 |
| Operating Margin % | -3,169.13 |
| Pre-tax Margin (%) | -8,230.20 |
| Quick Ratio | 0.01 |
| Current Ratio | 0.10 |
| ROA % (ttm) | -740.34 |
| ROE % (ttm) | -- |
| ROIC % (ttm) | -69.91 |
| Dividend Yield % | -- |
| Altman Z-Score | -103.82 |
ARTH Number of Guru Trades
ARTH Volume of Guru Trades
Gurus Latest Trades with OTCPK:ARTH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
OTCPK:ARTH is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Arch Therapeutics Inc Insider Transactions
No Available Data
News about OTCPK:ARTH
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers